2022年4月13日 · Hypercalcemia complicates the course of a variety of cancers when tumor factors overwhelm normal calcium and bone homeostasis. Cancer-associated hypercalcemia often occurs late in the...

2023年4月16日 · The most common solid tumors complicated by hypercalcemia include squamous cell carcinoma of the head, neck, and lungs, breast cancer, ovarian cancer, renal carcinoma, and a few hematological malignancies like leukemia.

Hypercalcemia of malignancy is estimated to affect over 40% of cancer patients and can be associated with both solid and blood cancers. Elevated calcium levels can be an indicator of developing cancer. The main mechanism of hypercalcemia development in tumors appears to be excessive production of parathyroid hormone-related peptides.

2024年5月2日 · The most common cancers associated with hypercalcemia in the United States are breast, renal, lung, and squamous cell cancers and multiple myeloma . Malignancy is usually evident clinically by the time it causes hypercalcemia, and patients with hypercalcemia of malignancy often have a poor prognosis.

2023年11月17日 · Hypercalcemia affects up to 30% of patients with cancer. 1 It has been seen in most cancers but is most common in patients with non-small cell lung cancer, breast cancer, multiple myeloma, head...

Hypercalcemia of malignancy is a common finding typically found in patients with advanced stage cancers. We aimed to provide an updated review on the etiology, pathogenesis, clinical presentation, and management of malignancy-related hypercalcemia.

2018年9月21日 · Presentations of these conditions range from asymptomatic disease incidentally detected on screening laboratory tests to severe metabolic derangements. This article reviews the causes of hypercalcemia in the patient with cancer and describes the diagnostic steps and treatment options for the most common causes of hypercalcemia.

Hypercalcemia of malignancy (HCM) affects 2% to 30% of patients with cancer and is associated with high morbidity and mortality.

Hypercalcemia of malignancy (HCM) is a common concern in patients being treated for cancer, affecting over a quarter of this population. There are multiple causes of HCM, including humoral HCM, osteolytic HCM, ectopic hyperparathyroidism, and vitamin D–secreting lymphomas.

Hypercalcemia can occur in those with malignancy and an additional etiology for hypercalcemia such as primary hyperparathyroidism or granulomatous diseases. This paper reviews the cancers associated with hypercalcemia and their proposed mechanisms, nontumor-mediated hypercalcemia, as well as diagnosis and treatment strategies for each condition.